Congresses

Titlesort descending Year
ESTUDIOS DE ELUCIDACIÓN DEL MODO DE ACCIÓN DE LAS AVERMECTINAS FRENTE A MYCOBACTERIUM 2019
Estudios iniciales para la caracterización del modo de acción molecular de las avermectinas como agentes anti-tuberculosos 2018
Expert Campus | Focus on tuberculosis 2020
Expert campus | Focus on tuberculosis 2020
Fighting Mycobacterium abscessus infection in Cystic Fibrosis patients 2020
Hollow fiber system for TB: optimization studies with Moxifloxacin 2022
Hollow fiber system for tuberculosis setting up at university of Zaragoza 2022
Implementing best practises on data generation and reporting of Mycobacterium tuberculosis time kill assays: a case study of standardized protocol within the ERA4TB consortium 2022
In vitro killing dynamics of the diarylquinolone TBAJ-587 and its main metabolites against Mycobacterium tuberculosis 2022
In vitro profiling of anthelmintic avermectins against non-tuberculous mycobacteria 2019
In vitro synergy screens of FDA-approved drugs combined with last-line antibiotics reveal new bactericidal combinations against Klebsiella pneumoniae 2022
In vitro time-kill assays of amoxicillin/clavulanate in combination with rifampicin/clarithromycin against Mycobacterium ulcerans 2022
Innovative drug discovery and development strategies for antibacterial therapy: a focus on neglected diseases  2017
Mathematical model of meropenem against Mycobacterium tuberculosis 2019
Mode of action elucidation studies of a new chemical series active against Mycobacteria and other microbial pathogens 2019
Mode of action elucidation studies of the avermectins against Mycobacteria 2019
Multicentric in-vitro characterization of MPL-204, a new anti- tuberculosis drug candidate, by the ERA4TB collaborative initiative 2022
New methodologies to test antibiotic susceptibility against emerging pathogens in cystic fibrosis 2019
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
Nuevos métodos para la búsqueda de combinaciones sinérgicas 2019

Pages